{"entity":{"id":"nct07468851","kind":"trial","name":"A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy","aka":[],"tldr":"A phase 1/2 trial of HS-10566 in bladder & urothelial cancer, run by Jiangsu Hansoh Pharmaceutical Co., Ltd., now recruiting.","summary":"A Study of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy is a phase 1/2 interventional study registered as NCT07468851 by Jiangsu Hansoh Pharmaceutical Co., Ltd., with 180 participants planned, started 2026-08-05 and due to reach its primary completion in 2028-04-30. Interventions recorded: HS-10566.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT07468851","url":"https://clinicaltrials.gov/study/NCT07468851"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["urothelial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT07468851","phase":"1/2","setting":"A Phase I/II Clinical Study Evaluating the Safety, Efficacy, Tolerability, and Pharmacokinetics of HS-10566 in Patients With High-risk Non-muscle-invasive Bladder Cancer Who Are Ineligible for or Refuse Radical Cystectomy","sponsor":"Jiangsu Hansoh Pharmaceutical Co., Ltd.","enrolled":180,"outcomes":[]},"route":"/trials/nct07468851/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"}]}}